For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed at $1.66 in the last session, down -5.68% from day before closing price of $1.76. In other words, the price has decreased by -$5.68 from its previous closing price. On the day, 18.48 million shares were traded.
Ratios:
We take a closer look at IOVA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.64 and its Current Ratio is at 4.18. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 14 ’25 when Vogt Frederick G bought 25,000 shares for $1.69 per share. The transaction valued at 42,250 led to the insider holds 374,646 shares of the business.
Maynard Ryan D sold 50,000 shares of IOVA for $503,000 on Nov 12 ’24. The Director now owns 7,500 shares after completing the transaction at $10.06 per share. On Nov 12 ’24, another insider, Maynard Ryan D, who serves as the Director of the company, bought 50,000 shares for $10.06 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 0.72.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $12.51, while it has fallen to a 52-week low of $1.65. The 50-Day Moving Average of the stock is -48.15%, while the 200-Day Moving Average is calculated to be -76.81%.
Shares Statistics:
A total of 333.93M shares are outstanding, with a floating share count of 271.61M. Insiders hold about 19.01% of the company’s shares, while institutions hold 62.86% stake in the company.
Earnings Estimates
The stock of Iovance Biotherapeutics Inc (IOVA) is currently drawing attention from 11.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.18 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.87 and -$1.42 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$0.75, with 11.0 analysts recommending between -$0.12 and -$1.14.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $66.65M. It ranges from a high estimate of $75.9M to a low estimate of $55.16M. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $31.11MFor the next quarter, 12 analysts are estimating revenue of $78.22M. There is a high estimate of $84.01M for the next quarter, whereas the lowest estimate is $73.81M.
A total of 12 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $300.4M, while the lowest revenue estimate was $261.65M, resulting in an average revenue estimate of $285.71M. In the same quarter a year ago, actual revenue was $164.07MBased on 12 analysts’ estimates, the company’s revenue will be $473.56M in the next fiscal year. The high estimate is $634.1M and the low estimate is $357.8M.
